Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). Pediatric AIDS Clinical Trials Group.

The current dosage of zidovudine for children is 180 mg/m2 every 6 h. To investigate whether a lower dosage was equally effective, human immunodeficiency virus (HIV)-infected children (3 months to 12 years) with mild to moderate symptoms were randomly assigned to receive either high-dose (180 mg/m2/dose) or low-dose (90 mg/m2/dose) zidovudine (double-blind). Treatments were compared with respect to neuropsychologic function, survival, clinical and laboratory evidence of disease progression, and safety and tolerance. Four hundred twenty-six HIV-infected children were enrolled; median time for receipt of study drug was 35 months. Zidovudine in either dose was well tolerated, with no difference in efficacy or tolerance by treatment group using any clinical or laboratory parameter. In children with mild to moderate disease, a reduction of zidovudine to 90 mg/m2/dose will result in substantial cost savings and should be the recommended dose.

[1]  D. Richman,et al.  A pilot study of low-dose zidovudine in human immunodeficiency virus infection. , 1990, The New England journal of medicine.

[2]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[3]  P. Kleihues,et al.  HIV Encephalopathy: Incidence, Definition and Pathogenesis , 1991, Acta pathologica japonica.

[4]  K Kim,et al.  Study duration for clinical trials with survival response and early stopping rule. , 1990, Biometrics.

[5]  D. Dickson,et al.  Pediatric acquired immunodeficiency syndrome. Neurologic syndromes. , 1988, American journal of diseases of children.

[6]  W. Rozenbaum,et al.  EFFECTS OF ZIDOVUDINE IN 365 CONSECUTIVE PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX , 1988, The Lancet.

[7]  C. Giaquinto,et al.  Neurologic signs in young children with human immunodeficiency virus infection , 1990 .

[8]  W. Parks,et al.  Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. , 1990, The Journal of pediatrics.

[9]  D. Kurtzberg,et al.  Neurological complications in infants and children with acquired immune deficiency syndrome , 1985, Annals of neurology.

[10]  W. Shearer,et al.  A national survey on the care of infants and children with human immunodeficiency virus infection. , 1991, Jornal de Pediatria.

[11]  M. Wulfsohn,et al.  A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome , 1990 .

[12]  H. Ruff,et al.  DEVELOPMENTAL ABNORMALITIES IN INFANTS AND CHILDREN WITH ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) AND AIDS‐RELATED COMPLEX , 1985, Developmental medicine and child neurology.

[13]  D. Mack,et al.  Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). , 1988, Annals of internal medicine.

[14]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[15]  H. Moss,et al.  Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. , 1990, The Journal of pediatrics.

[16]  S. Wyard,et al.  THE NATURAL DURATION OF CANCER , 1925, Canadian Medical Association journal.

[17]  L. Epstein,et al.  Expression of human immunodeficiency virus in cerebrospinal fluid of children with progressive encephalopathy , 1987, Annals of neurology.

[18]  H. Moss,et al.  Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response. , 1993, The Journal of infectious diseases.

[19]  Lee-Jen Wei,et al.  Combining dependent tests with incomplete repeated measurements , 1985 .

[20]  C. Decarli,et al.  The prevalence of computed tomographic abnormalities of the cerebrum in 100 consecutive children symptomatic with the human immune deficiency virus , 1993, Annals of neurology.

[21]  M. Wulfsohn,et al.  A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. , 1991, The New England journal of medicine.

[22]  Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV Infection , 1988 .

[23]  G. di Chiro,et al.  Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Douglas D. Richman,et al.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial , 1990 .

[25]  L. Epstein,et al.  Neurologic manifestations of human immunodeficiency virus infection in children. , 1986, Pediatrics.

[26]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[27]  E. Lehmann,et al.  Nonparametrics: Statistical Methods Based on Ranks , 1976 .

[28]  C. Decarli,et al.  Brain growth and cognitive improvement in children with human immunodeficiency virus-induced encephalopathy after 6 months of continuous infusion zidovudine therapy. , 1991, Journal of acquired immune deficiency syndromes.

[29]  P. Reiss,et al.  RESUMPTION OF HIV ANTIGEN PRODUCTION DURING CONTINUOUS ZIDOVUDINE TREATMENT , 1988, The Lancet.

[30]  N. Bayley.  Manual for the Bayley Scales of Infant Development , 1969 .